Actively Recruiting
Led by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2026-04-28
40
Participants Needed
1
Research Sites
N/A
Total Duration
Osteoarthritis (OA) of the knee is a common and increasing form of arthritis worldwide, particularly affecting older adults. This research aims to compare the effects of 99Tc-MDP, a drug previously used for rheumatoid arthritis and other bone diseases, with celecoxib, a commonly prescribed oral anti-inflammatory medication, in patients with knee OA. The study is designed to better understand how these treatments may help control symptoms and potentially slow disease progression in this population. Participants will receive either 99Tc-MDP or celecoxib. The 99Tc-MDP group will be given 15 mg of the drug intravenously in 100 ml of normal saline twice weekly for 5 weeks, then weekly for 10 weeks, every 2 weeks for another 10 weeks, and finally once a month for 6 months. The celecoxib group will take a 200 mg capsule orally once daily. The study is non-randomized and open-label, meaning both participants and researchers know which treatment is given. Throughout the study, participants will be assessed at baseline and at 6 and 12 months after treatment starts. Evaluations will include pain, stiffness, and knee joint function, as well as quality of life, disease staging, and imaging measurements using bone scans. Safety will be monitored by tracking any adverse events at 3, 6, and 12 months. The total participation time covers these follow-up periods to understand the treatments' effects over time.
CONDITIONS
99Tc-MDP Treatment for Knee Osteoarthritis
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 8 months
Participants receive either 99Tc-MDP intravenously with varying frequency over several months or daily oral celecoxib to manage knee osteoarthritis symptoms.
Multiple visits corresponding to dosing schedule: twice a week for 5 weeks, weekly for 10 weeks, biweekly for 10 weeks, then monthly for 6 months (99Tc-MDP group); daily oral dosing for celecoxib group with visits for assessments
Duration - Up to 12 months after treatment
Participants are monitored for pain, stiffness, joint function, quality of life, and adverse events up to 12 months after treatment begins.
Visits at 3, 6, and 12 months after treatment for outcome assessments and safety monitoring
Total: 1 location
1
Department of Nuclear Medicine, Tenth People's Hospital of Tongji University
Shanghai, Shanghai Municipality, China, 200072
Actively Recruiting
C
Chao Ma, MD
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Kunbei Lai, Li Xu, Chenjin Jin...
https://pubmed.ncbi.nlm.nih.gov/21666238Marc C Hochberg, Roy D Altman, Karine Toupin April...
https://pubmed.ncbi.nlm.nih.gov/22563589T Boegård, O Rudling, J Dahlström...
https://pubmed.ncbi.nlm.nih.gov/10343536H-R Kim, Y So, S-G Moon...
https://pubmed.ncbi.nlm.nih.gov/17662626Hongjuan Liu, Huili Guo, Shunong Guo...
https://pubmed.ncbi.nlm.nih.gov/27327630F McCrae, J Shouls, P Dieppe...
https://pubmed.ncbi.nlm.nih.gov/1417117